Manufacturing Costs of HPV Vaccines for Developing Countries

This article, published in Vaccine, details an analysis designed to estimate the manufacturing costs (including annualized capital costs, vaccine yield, raw materials, manufacturing personnel, factory/administrative overheads, and filling/packaging) of the quadrivalent human papillomavirus (HPV) vaccine, Gardasil®-4, and the bivalent HPV vaccine, Cervarix. The authors estimate that the actual manufacturing cost of both vaccines is less than the reported cost for developing countries. They conclude that reducing the procurement price for Gavi, the Vaccine Alliance could promote more widespread vaccine adoption in low- and middle income countries while still allowing manufacturers to retain profits.

Author: Clendinen C, Zhang Y, Warburton RN, Light DW

Published: 2016

» Visit web page (English)

(Located at

Citation: Clendinen C, Zhang Y, Warburton RN, Light DW. Manufacturing Costs of HPV Vaccines for Developing Countries. Vaccine. 2016;34(48):5984-5989.

Resource types: Peer-reviewed journal

Diseases/vaccines: Human papillomavirus (HPV)

Topics: Immunization financing, Disease/vaccine specific information

Regions: Global